PORTO, Portugal–(BUSINESS WIRE)–Flow Eighteen38, a protein science division created to facilitate and accelerate antibody characterization and protein purification projects, today announced an investment of $5 million euros (approximately US$5.58 million) in its protein production and parent company biophysical characterization capabilities and services, FairJourney Biologics SA (FJB), leaders in antibody discovery and optimization.
The investment will be used to develop a dedicated and suitable laboratory, designed to house a range of new and bespoke state-of-the-art equipment to double protein purification capacity. The new facilities will house more than 15 high-end fast protein liquid chromatography (ÄKTA) systems, all individually optimized to scale custom production, as well as meet unique partner requirements and accelerate standard productions.
The investment will also streamline quality control through the purchase of high-throughput, high-precision equipment, including LabChip® GX Touch™ for CE-SDS, Thermo Scientific Vanquish UHPLC, Endosafe nexgen – FDA licensed MCS for endotoxin testing and two BioAccord™ LC-MS systems for biopharmaceutical analysis. Additionally, the funding will drive recruitment to meet the increased demand for production and characterization services, as well as Flow Eighteen38 cold storage and logistics solutions, and the continued supply of quality antibody reagents in line with the new recommendations of the EU.
António Parada, CEO of FairJourney Biologics commented: “This investment is an additional commitment to our partners to ensure that we remain at the forefront of protein production and biophysical solutions and to continue to deliver quality results that our diverse portfolio of partners have come to know and expect. “
Teresa Barata, Head of Protein Science Division at Flow Eighteen38, commented: “We are delighted with this new step of Flow Eighteen38. The new investment will allow us to continue to accompany our customers at the different stages of the discovery process and to extend it to the pre-CMC stages, for faster and more successful biotherapeutic development.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220308005678/en/